Carboxymethyl-starch excipients for gastrointestinal stable oral protein formulations containing protease inhibitors

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 1, 2010, Pages 78-92

  de Koninck, Patrick ^a,b   Archambault, Denis ^a,b,c,d   Hamel, Francine ^a,b   Sarhan, Fathey ^a   Mateescu, Mircea Alexandru ^a,b,c,d  

^a Department of Chemistry ^*

^b Centre BioMed

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CARBOXYMETHYLSTARCH SODIUM; CHLOROACETIC ACID; PROTEINASE INHIBITOR; TRIACYLGLYCEROL LIPASE; 4 (2 AMINOETHYL)BENZENESULFONYLFLUORIDE; 4-(2-AMINOETHYL)BENZENESULFONYLFLUORIDE; APROTININ; CARBOXYMETHYL STARCH; DRUG DERIVATIVE; EXCIPIENT; PLANT EXTRACT; STARCH; SULFONE; TRYPSIN INHIBITOR;

ALFALFA; ARTICLE; DENSITOMETRY; DISSOLUTION; DRUG FORMULATION; ENZYME ACTIVITY; INTESTINE FLUID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; PROTEIN STABILITY; STOMACH JUICE; STOMACH PH; ANIMAL; CATTLE; CHEMISTRY; INTESTINE SECRETION; METABOLISM; ORAL DRUG ADMINISTRATION; TABLET;

ADMINISTRATION, ORAL; ANIMALS; APROTININ; CATTLE; DENSITOMETRY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXCIPIENTS; GASTRIC JUICE; INTESTINAL SECRETIONS; LIPASE; MEDICAGO SATIVA; PLANT EXTRACTS; PROTEIN STABILITY; SERUM ALBUMIN, BOVINE; STARCH; SULFONES; TABLETS; TRYPSIN INHIBITORS;

EID: 77955490545     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3b01f     Document Type: Article

References (27)

1. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine, 2003; 21: S2/89-S2/95.
2. Huang Z, Dry I, Webster D, Struynell R, Wesselingth S. Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine, 2001; 19: 2163-2171.
3. Streatfield SJ, Lane JR, Brooks CA, Barker DK, Poage ML, Mayor JM, Lamphear BJ, Drees CF, Jilka JM, Hood EE, Howard JA. Corn as a production system for human and animal vaccines. Vaccine, 2003; 21: 812-815.
4. Erickson, L.; Yu, W.J.; Brandle, J.; Rymerson, R., Molecular Farming of Plants and Animals for Human and Veterinary Medicine. Kluwer Academic Publishers, the Netherlands, 2002.
5. Acheson DW, Luccioli S. Microbial-gut interactions in health and disease. Mucosal immune responses. Best Pract Res Clin Gastroenterol, 2004; 18: 387-404.
6. Kerneis S, Bogdanova A, Kraehenbuhl J-P, Perringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Sciences, 1997; 277: 949-952.
7. Ogra PL, Faden H, Welliver RC. Vaccination atrtegies for mucosal immune responses. Clin Microbiol Rev, 2001; 14: 430-445.
8. Langguth P, Bohner V, Heizmann J, Merkle HP, Wolffram S, Amidon GL, Yamashita S. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release, 1997; 46: 39-57.
9. Roper H. Applications of starch and its derivatives, Carbohydr Eur, 2001; 15: 14-21.
10. Mulhbacher J, Ispas-Szabo P, Mateescu MA. Cross-linked high amylose starch derivatives for drug release. II. Swelling properties and mechanistic study. Int J Pharm, 2004; 278: 231-238.
11. Calinescu C, Mulhbacher J, Nadeau E, Fairbrother JM, Mateescu MA. Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations. Eur J Pharm Biopharm, 2005; 60: 53-60.
12. Calinescu C, Nadeau E, Mulhbacher J, Fairbrother JM, Mateescu MA. Carboxymethyl high amylose starch for F4 fimbriae gastroresistant oral formulations. Int J Pharm, 2007; 343: 18-25.
13. Massicotte LP, Baille WE, Mateescu MA. Carboxylated high amylose starch as pharmaceutical excipients: Structural insights and formulation of pancreatic enzymes. Int J Pharm, 008; 356: 212-223.
14. Brouillet F, Bataille B, Cartilier L. Highamylose sodium carboxymethyl starch matrices for oral, sustained drug-release: formulation aspects and in vitro drug-release evaluation. Int J Pharm, 2008; 356: 52-60.
15. Hsieh CC, Hernández-Ledesma B, Jeong HJ, Park JH, de Lumen BO. Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PLoS One, 2010; 5: e8890.
16. Esposito E, Cortesi R, Bortolotti F, Manegatti E, Nastruzzi C. Production and characterization of biodegradable microparticles for the controlled delivery of proteinase inhibitors. Int J Pharm, 1996; 129: 263-273.
17. Shi C, Zhao X, Wang X, Zhao L, Andersson R. Potential effects of PKC or protease inhibitors on acute pancreatitis-induced tissue injury in rats. Vascul Pharmacol, 2007; 46: 406-411.
18. Larionova NV, Ponchel G, Duchêne D, Larionova NI. Biodegradable cross-linked starch:protein microcapsules containing proteinase inhibitor for oral protein administration. Int J Pharm, 1999; 189: 171-178.
19. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, Muranishi S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res, 1994; 11: 1496-1500.
20. Tiourina, O., Hamdi, G., Larionova, N., Duchene, D., Ponchel, G., Preparation and characterization of polymethacryloyl starch microspheres loaded with basic pancreatic trypsin inhibitor. Proc. 2nd World Meeting Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, Paris, pp. 539-540, 1998.
21. Dentan C, Tselepis AD, Chapman MJ, Ninio E. Pefabloc, 4-[2 aminoethyl]-benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta, 1996; 1299: 353-357.
22. Westberg C, Benkestock K, Fatouros A, Svensson M, Sjostrom B. Hexarelin-evaluation of factors influencing oral bioavailability and ways to improve absorption. J Pharm Pharmacol, 2001; 53: 1257-1264.
23. Schell HD, Serban M, Mateescu MA, Bentia T. Acid and basic amylose ionic exchangers. Rev Roumaine Chim, 1978; 23: 1143-1147.
24. Capraro J, Magni C, Scarafoni A, Duranti M. Susceptibility of lupin gamma-conglutin, the plasma glucose-lowering protein of lupin seeds, to proteolytic enzymes. J Agric Food Chem, 2009; 57: 8612-8616.
25. Sauer D, Zheng W, Coots LB, McGinity JW. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55. Eur J Pharm Biopharm, 2007; 67: 464-475.
26. Zhao N, Augsburger LL. Functionality Comparison of 3 Classes of Superdisintegrants in Promoting Aspirin Tablet Disintegration and Dissolution. AAPS PharmSciTech, 2005; 6: E634-E640.
27. Verdonck F, Joensuu JJ, Stuyven E, De Meyer J, Muilu M, Pirhonen M, Goddeeris BM, Mast J, Niklander-Teeri V, Cox E. The polymeric stability of the Escherichia coli F4 (K88) fimbriae enhances its mucosal immunogenicity following oral immunization. Vaccine. 2008; 26: 5728-5735.